Personalis, Inc. Accretion Expense
Personalis, Inc. (PSNL) reported Accretion Expense of $156.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2021-02-25
- Personalis, Inc. accretion expense for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- Personalis, Inc. accretion expense for the quarter ending 2019-09-30 was $53.00K, a 77.64% decline year-over-year.
- Personalis, Inc. accretion expense for the quarter ending 2019-06-30 was $81.00K.
- Personalis, Inc. accretion expense for the quarter ending 2019-03-31 was $22.00K.
- Personalis, Inc. accretion expense for fiscal 2019 was $156.00K, a 86.87% decline from fiscal 2018.
- Personalis, Inc. accretion expense for fiscal 2018 was $1.19M, a 28.02% increase from fiscal 2017.
- Personalis, Inc. accretion expense for fiscal 2017 was $928.00K.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $53.00K derived: sum of 2 quarters · filed 2021-02-25 | $134.00K derived: sum of 3 quarters · filed 2021-02-25 | $156.00K 10-K · filed 2021-02-25 |
| 2019-09-30 | $53.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $134.00K derived: sum of 2 quarters · filed 2020-11-05 | $156.00K 10-Q · filed 2020-11-05 | $207.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $81.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $103.00K 10-Q · filed 2020-08-06 | $154.00K derived: sum of 3 quarters · filed 2021-02-25 | $391.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $22.00K 10-Q · filed 2020-05-07 | $73.00K derived: sum of 2 quarters · filed 2021-02-25 | $310.00K derived: sum of 3 quarters · filed 2021-02-25 | |
| 2018-12-31 | $51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $288.00K derived: sum of 2 quarters · filed 2021-02-25 | $1.19M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $237.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $1.14M 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | $900.00K 10-Q · filed 2019-08-13 | |||
| 2017-12-31 | $928.00K 10-K · filed 2020-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |